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b Howard Hughes Medical Institute, Chevy Chase, MD, USAMycobacterium tuberculosis (Mtb) is one of the most successful The failure to control the global TB epidemic despite the availability
human pathogens, and a key mechanism in its virulence arsenal is its
ability to inﬂuence host immune responses to its advantage. In recent
years it has become clear that one such mechanism pivots on
bacterial-derived, secreted small molecules that are released from the
intracellular phagosome of macrophages into the host cell cytosol
where they interfere with host cell signaling and downstream cytokine
responses. Using small molecules such as cyclic nucleotides, Mtb sub-
verts the host's innate bactericidal responses to remodel the intracellu-
lar niche to an environment favorable for mycobacterial survival or
growth (Agarwal et al., 2009; Dey et al., 2015; Tobin et al., 2012;
Wallis and Hafner, 2015).
A key bacterial-derived, secreted small molecule is the well-known
second messenger cyclic adenosine monophosphate (cAMP). Upon
infection Mtb produces a burst of cAMP within macrophages. Through
a microbial adenylate cyclase gene, bacterial-derived cAMP is delivered
to themacrophage cytoplasm increasing cytosolic cAMP levels 3–5-fold
above baseline and triggering the PKA-CREB pathway to upregulate
NFκB transcription. One consequence of bacterial subversion of host
cAMP signaling is the elevated TNF-α secretion at the early stages of
infection promoting necrosis and granuloma formation—outcomes
that foster bacterial survival (Agarwal et al., 2009).
Mtb also interferes with immune signaling by secreting another
bacterial-derived second messenger, cyclic-di-adenosine monophos-
phate (c-di-AMP) (Dey et al., 2015). This pathogen-associated molecu-
lar pattern (PAMP) which is recognized by the macrophage cytosolic
surveillance pathway behaves as a double-edged sword in Mtb patho-
genesis. On the one hand, it contributes to the induction of Type I inter-
feron levels through the STING-IRF3 signaling pathway, enhancing
immunopathology and thus beneﬁting the microbe. On the other
hand, c-di-AMP also enhances autophagy and bacterial killing. Mtb
expressing excess c-di-AMP displays a loss of pathogenicity in animal
models indicating that the dominant impact of microbial c-di-AMP
production is its stimulation of autophagy to beneﬁt the host (Dey
et al., 2015). This latter observation suggests that measures to prevent
the breakdown of Mtb-derived c-di-AMP might be beneﬁcial for host
control of tuberculosis (TB).DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2016.01.015.
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maintaining continuous chemotherapy over at least six months (WHO,
2015). Moreover, even when patients are cured from the disease, lung
function is often never fully recovered. As such, adjunctive host-
directed therapies (HDTs) for TB are currently being explored to
improve treatment outcomes by restoring effective host immunity,
achieving an appropriate degree of inﬂammation, and preventing
disease-associated lung pathology (Wallis and Hafner, 2015). Success
in modulating immunity may also lead to treatment shortening by
reducing granulomatous pathology and the bacterial persister-state as-
sociated with granulomas.
Small molecule phosphodiesterase (PDE) inhibitors – which raise
levels of certain cytosolic cyclic nucleotides – have become important
drugs in human medicine with the introduction of PDE3 inhibitors for
intermittent claudication, PDE5 inhibitors for erectile dysfunction and
pulmonary hypertension, and PDE4 inhibitors for chronic obstructive
pulmonary disease. PDE4 inhibitors have been of particular interest
for lung infections since they reduce pulmonary inﬂammation. Not sur-
prisingly, the evaluation of FDA-approved human PDE inhibitors aswell
as those in the pipeline for FDA approval has emerged as an attractive
strategy for adjunctive HDTs against TB.
PDE inhibitors are isoenzyme-speciﬁc compounds of different bind-
ing afﬁnities and potencies that also act according to the tissue distribu-
tion of the isozyme (Wang and Cui, 2006). Several PDE inhibitors have
already shown varying degrees of success as adjunctive TB treatment
agents (Maiga et al., 2013, 2015; Subbian et al., 2011). Addition of an
experimental PDE4 inhibitor—rolipram—to standard TB therapy in the
mousemodel, for example, had no impact on the rate of bacterial clear-
ance at six months (Maiga et al., 2013). However, more recently
roﬂumilast, an FDA approved PDE4 inhibitor was shown to augment
the action of isoniazid in an 8-week mouse model (Maiga et al., 2015).
Furthermore, other PDE classes have also shown beneﬁt. Addition of
the PDE3 inhibitor cilostazol or the PDE5 inhibitor sildenaﬁl reduced
bacterial clearance and accelerated the time-to-tissue sterilization by
up to one month when added to the full 6-month standard regimen in
a mouse model (Maiga et al., 2013).
In this issue, Subbian et al. assess the adjunctive value of the PDE in-
hibitor CC-11050 when used in combination with isoniazid to treat TB
(Subbian et al., 2016). CC-11050, which is currently in clinical trials for
other indications, is a new PDE4 inhibitor. Using the rabbit model of
TB, Subbian and colleagues showed that adjunctive use of CC-11050the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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burden. They further demonstrated that the drug dampens the TNF-α
regulatory network, reduces macrophage activation and the lung
inﬂammatory responses, and it lessens pulmonary ﬁbrosis and necrosis
(Subbian et al., 2016). This CC-11050-speciﬁc effect is attributable to its
host modulatory properties as it had no antibacterial activity or
apparent drug–drug interactions with isoniazid. These data demon-
strate that CC-11050 has activity as an adjunctive HDT and could
potentially shorten the duration of TB treatment (Subbian et al.,
2016). As with CC-3052 and roﬂumilast, the beneﬁcial effect of CC-
11050 was observed at approximately 8-weeks post-treatment
(Maiga et al., 2015; Subbian et al., 2011, 2016). While it remains un-
known how CC-11050 will perform beyond this time period, the re-
duced inﬂammatory response and associated increased bactericidal
activity of isoniazid may result in fewer bacilli entering persister-
state. It is also tempting to speculate that the reduced ﬁbrosis ob-
served may lead to alterations in granuloma structure allowing for
greater antibiotic penetration. It will be important to assess CC-
11050with a full multidrug therapy and accompanying relapse stud-
ies to determine if the 8-week study combining CC-11050 with a
single antibiotic will translate into a beneﬁt when the drug is
added to a 6-month multidrug therapy. Nonetheless, given the ex-
plosive growth of immunomodulatory drugs entering clinical use
for inﬂammatory diseases, these ﬁndings continue to offer room for
optimism that TB-dysregulated immunity may be corrected pharma-
cologically by HDTs. The challenge will be to determine the right
cocktail and timing of these potent immunomodulators with tried-
and-true multidrug antibiotic therapy.Disclosure
The authors have no relevant conﬂicts of interest to disclose.
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